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Abstract: The impact of the COVID-19 pandemic on our lives is unquestionable, including in the
area of substance consumption. This study aimed to evaluate the changes in the pattern of cannabis
use during the Spanish COVID-19 lockdown and confinement, and to analyze the variations in
the reported motives for cannabis use and withdrawal symptoms. A cross-sectional retrospective
study was conducted between April and May 2020, using an instrument that included two time
points. Time 1 collected retrospective information on the participants’ habits (N = 89; 73% male; mean
age = 29.01) prior to confinement and Time 2 collected the same information during the confinement.
Sociodemographic data were collected, as well as the frequency of substance use, cannabis use
patterns, sources of cannabis, perceived availability of drugs and cannabis price, and the Marijuana
Motives Measure questionnaire and the Cannabis Withdrawal Scale were used. Results showed a
decrease in both cannabis use and consumption due to enhancement and social motives. All reported
sources of cannabis experienced a reduction except for the Internet, which experienced a significant
increase. There was a positive correlation between withdrawal symptoms and coping motives before
and during the lockdown. These findings will allow professionals to better develop both prevention
and intervention strategies.
Keywords: cannabis; confinement; COVID-19; lockdown; Spain
1. Introduction
The COVID-19 pandemic and the necessary quarantines have had a considerable
impact on everyone’s lives. Despite abundant information on the impact of the present
and previous pandemics on public health, the economy or other issues [1], no previous
information exists on the impact of a pandemic on substance use and substance use
disorders (SUD). A report from the European Monitoring Centre on Drugs and Drug
Addiction (EMCDDA) concluded that during the initial months of the pandemic there
was an overall decline in drug use, particularly for recreational drugs such as cocaine and
MDMA, due to the national confinements [2].
However, and for the first time, the COVID-19 pandemic has expanded the focus
to the impact of pandemics on our mental health, and considerable research has already
been carried out. The main results of previous studies indicate that negative psychological
consequences include stress, insomnia, depression, fear, post-traumatic stress symptoms,
confusion and anger, as well as unhealthy behaviors such as excessive substance use [3–6].
Moreover, people with pre-existing medical and psychiatric conditions as well as substance
use problems seem to have been at greater risk of adverse psychosocial outcomes [5]. In
particular, previous studies have shown that both chronic social isolation and loneliness
Int. J. Environ. Res. Public Health 2021, 18, 11324. https://doi.org/10.3390/ijerph182111324 https://www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2021, 18, 11324 2 of 8
were significantly higher during the COVID-19 pandemic, which is of great concern given
the association of these factors with increased depression and suicidal ideation [7].
Regarding cannabis, Europe’s most commonly used illicit drug [8], results remain
unclear. In general, research has mainly focused on alcohol and smoking use during the
pandemic, whereas little attention has been paid to cannabis use and abuse [3]. Recent stud-
ies indicate that cannabis use increased during the pandemic in various countries [3,9–12].
In fact, this might have resulted in more emergency department admissions during lock-
down compared to the corresponding weeks of 2019 [13].
To date, only a few studies have evaluated the possible factors behind such changes,
including the impact of lockdowns on the motives for cannabis use, the perceived avail-
ability, withdrawal symptoms, the use of other substances or the sources used to obtain
cannabis. Cannabis users who engaged in recommended/mandated self-isolation due
to the COVID-19 pandemic were using 20% more cannabis than those who did not [3].
Previous research conducted during non-pandemic periods indicated that motivations for
cannabis use are important for understanding cannabis use problems and disorders [14–16].
In Belgium, it has been reported that boredom, lack of social contacts, loss of daily structure,
desire for a reward after a hard working day, loneliness and conviviality were associated
with increased substance use (including cannabis) during lockdown [11]. However, this
study provided limited information, due to the lack of a validated instrument, a thorough
evaluation, and a specific analysis of cannabis use patterns. Furthermore, some studies
also indicated that not only have consumers increased their cannabis use but also the fre-
quency of use, since one-third of users became daily consumers during the lockdown [17].
Moreover, this last study highlighted the fact that changes in the pattern of cannabis use
might have had an impact on the use of other substances, such as tobacco, alcohol and ben-
zodiazepines [17]. Regarding changes in cannabis availability, research is also scarce [18].
In Europe, Europol and the EMCDDA [19] reported a shortage of cannabis (resin) as well
as some difficulties in accessing the substance in some European countries. In addition, an
analysis of three major marketplaces revealed a remarkable increase in cannabis trafficking
between January and March 2020 [18,20].
Beyond this preliminary literature regarding the impact of the COVID-19 pandemic
on cannabis use in the European context, no published studies have accounted for possible
changes in the pattern of cannabis consumption during the lockdown period focusing on
frequency, motives for use, availability or withdrawal symptomatology among Spanish
participants. The present research aims to address this gap in the literature, especially
considering the particularly strict lockdown measures that were enforced in Spain due to
the pandemic situation. The unprecedented lockdown was imposed on 14 March until 21
June, 2020. The Spanish authorities undertook exceptional measures based on a mandatory
confinement period, when much of the economic activity ceased for several weeks and all
non-essential workers were ordered to stay at home, therefore encouraging social isolation.
The main goals of this study were (1) to evaluate changes in the pattern of cannabis use in
the Spanish population during the confinement associated with the state of alarm in Spain
and (2) to evaluate changes in motivations for cannabis use and withdrawal symptoms
among cannabis users.
2. Materials and Methods
The current research was a cross-sectional retrospective investigation conducted be-
tween April and May 2020. During this period, the first declaration of a state of alarm in
Spain, entailing a mandatory and strict national confinement, was enforced. The instru-
ment used in the study consisted of two sections, evaluating two different time points.
Time 1 collected retrospective information on participants’ habits (i.e., their habits im-
mediately before the state of alarm was enforced), and Time 2 collected information on
the current using habits and patterns during the mandatory national confinement. All
instruments were computerized and administered online. The battery was disseminated
through multiple social platforms and institutional websites. All participants provided
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their informed consent. This study was approved by the Ethics Committee of Universidad
Loyola Andalucía.
2.1. Participants
The inclusion criteria were (1) being 18 years of age or older and (2) having used
cannabis at least once in the previous 30 days at Time 1. A total of 147 participants provided
informed consent and agreed to participate. Overall, 58 questionnaires were discarded as
they were incomplete or filled out erratically. The final sample consisted of 89 participants
(60.54% of the initial sample) who completed the full survey (73% male; mean age = 29.01,
SD = 9.26; mean age of onset of cannabis use = 16.14, SD = 3.09).
2.2. Instruments
Sociodemographic information was collected by means of a questionnaire collecting
information on sex, age, age of onset of cannabis use and days passed since the enforcement
of the state of alarm and the subsequent national confinement (in Spain, 14 March 2020).
2.2.1. Frequency of Substance Use
The numbers of occasions of cannabis and tobacco use in the previous week were
evaluated at Time 1 and 2 with Likert-type response items with the following options:
never, 1–2 times, 3–5 times, 6–9 times, 10–19 times, 20–29 times, 30 times or more.
2.2.2. Cannabis Use Patterns
The frequency of use of the different cannabis forms (marijuana only, hashish only,
marijuana and tobacco, hashish and tobacco, synthetic cannabinoids, cannabidiol prod-
ucts or other cannabis products) at Time 1 and Time 2 was evaluated with a Likert-type
response format including the following answers: never, almost never, sometimes, nearly
always, always.
2.2.3. Sources of Cannabis
The frequency of use of different sources of cannabis (friends, relatives, cannabis clubs,
Internet or dealers) at Time 1 and Time 2 was evaluated with a Likert-type response format
including the following answers: never, almost never, sometimes, nearly always, always.
2.2.4. Perceived Availability of Drugs
The perceived availability of different drugs (marijuana, hashish, other cannabinoid
products, tobacco and cocaine) was evaluated at Time 1 and Time 2 with a Likert-type
response format with answers ranging from 1 (very difficult or nearly impossible) to 5
(easy or very easy). The questions were extracted from the Spanish survey on drug use
among secondary-school-age youths (ESTUDES).
2.2.5. Cannabis Price
Participants were asked about the estimated price they usually paid for the equivalent
amount of cannabis necessary to roll a joint at Time 1. Also, they were asked about the
price they had paid at the last time of purchase since the declaration of the state of alarm
(Time 2). In case they had not paid for cannabis during this time, the hypothesized price
they would have to pay was collected. The possible response options included: EUR 0.50,
EUR 1, EUR 1.5, EUR 2, EUR 2.5, EUR 3, EUR 4, EUR 5, EUR6 and more than EUR 6.
2.2.6. Cannabis Use Motives
The Spanish version of the Marijuana Motives Measure (MMM) [21,22] was used to
evaluate the reasons reported by participants for their cannabis use at Time 1 and Time 2.
The MMM is a self-reported questionnaire made up of 25 questions evaluating five different
dimensions, namely, social, enhancement, coping, expansion and conformity. Response
options have a Likert-type format with the following answers: almost never, sometimes,
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half of times, most times, nearly always/always. The overall reliability of the Spanish
validation was Cronbach’s alpha = 0.86, with the reliability of subscales ranging from 0.64
to 0.83.
2.2.7. Cannabis Withdrawal Symptoms
The Cannabis Withdrawal Scale (CWS) [23] was used to evaluate the severity of
cannabis withdrawal at Time 2. The questionnaire was translated and adapted following
the corresponding international guidelines [24]. The questionnaire was translated into
Spanish by a bilingual researcher and expert on cannabis, and then back translated into
English by two native English speakers. Possible inconsistencies were discussed until a
final agreement between experts was reached on the final translation. The CWS is made up
of 19 items on the prevalence of different symptoms of cannabis withdrawal in the previous
24 h. Responses have a Likert-type format ranging from 0 (not at all) to 10 (extremely). The
original version had a reliability of Cronbach’s alpha = 0.91 [23], and the current version a
reliability of Cronbach’s alpha = 0.87.
2.3. Data Analyses
Firstly, and to analyze the possible changes in the pattern of cannabis use associated
with the state of alarm, bivariate analyses were carried out to evaluate differences in
cannabis use, cannabis use patterns, perceived availability of drugs and cannabis prices
between T1 and T2. In all cases, effect sizes were calculated where possible (phi for
categorical variables and Cohen’s d for continuous variables). Secondly, bivariate analyses
were used to evaluate the association between motives for cannabis use and withdrawal
symptoms. More specifically, Pearson correlations were used. In all cases, confidence
intervals of 95% were used. Finally, the statistical package used was IBM SPSS Version 26.
3. Results
Table 1 reports changes in the pattern of cannabis and tobacco use, as well as in the
sources used to obtain cannabis. A significant increase was detected in the percentage
of participants abstaining from tobacco use (p < 0.001), and significant decreases were
reported in the use of all forms of cannabis (p < 0.05) except for CBD products, where no
significant changes were detected. Significant decreases were detected in the use of most
sources of cannabis (p < 0.05) except the Internet, which experienced a significant increase
(p = 0.001). The average price paid for the amount of cannabis necessary to roll a joint also
increased significantly. Among cannabis users who had not bought marihuana in the last
week at T2, the hypothesized price also increased significantly.
Table 2 reports the changes in the perceived availability of different forms of cannabis
as well as other drugs. Significant decreases in perceived availability were detected for all
drugs, including tobacco (p < 0.05). With regard to the motives for cannabis use, significant
decreases were detected in the use of cannabis for enhancement, conformity and social
motives (p < 0.05).
Finally, Table 3 indicates that a significant correlation existed, both before and during
the SA, between cannabis withdrawal symptoms and cannabis use for coping motives
(r = 0.338, p < 0.05 and r = 0.327, p < 0.05, respectively).
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Table 1. Changes in patterns of substance use between Time 1 and Time 2.
Time 1 Time 2 Statistic p Effect Size
Weekly tobacco use 4.13 3.82 1.764 0.081 -
Weekly cannabis use 5.09 4.80 1.845 0.068 -
Abstained from tobacco last week 28.1% 37.1% 37.07 <0.001 * Phi 0.607
Abstained from cannabis last week 0% 8.0% - 1.000 * -
Frequency of cannabis use forms
Marijuana only 2.48 1.97 4.816 <0.001 d = 0.51
Hashish only 1.42 1.21 2.304 0.024 d = 0.24
Marijuana + tobacco 3.62 3.01 4.760 <0.001 d = 0.50
Hashish + tobacco 3.37 2.83 4.217 <0.001 d = 0.45
Vaporized 1.79 1.47 4.693 <0.001 d = 0.50
Spice 1.11 1.04 2.165 0.033 d = 0.23
CBD 1.64 1.52 1.33 0.187 -
Others 1.81 1.43 4.931 <0.001 d = 0.52
Sources
Friends 67.4% 36.0% 17.701 <0.001 Phi 0.471
Family 20.2% 11.2% - <0.001 * Phi 0.618
Cannabis clubs 56.2% 12.4% - 0.020 * Phi 0.263
Internet 4.5% 6.7% - 0.001 * -
Dealer 77.5% 46.1% 11.699 0.001 Phi 0.390
EUR/joint (paid before SA—paid during SA) 1.33 (0.99) 1.77 (1.53) −2.541 0.015 d = 0.39
EUR/joint (paid before SA–hypothesized during SA) 1.55 (1.10) 2.06 (1.51) ** −2.799 0.008 d = 0.45
* Fisher’s Exact Test; ** Hypothesized.
Table 2. Changes in perceived availability and motives for cannabis use.
Time 1 Time 2 t p Cohen’sd
Perceived availability
Marijuana 4.39 (1.17) 2.49 (1.50) 10.24 <0.001 ** 1.12
Hashish 4.31 (1.15) 2.41 (1.44) 9.44 <0.001 ** 1.09
Other cannabis products 3.38 (1.43) 1.79 (1.12) 6.94 <0.001 ** 0.93
Tobacco 4.81 (0.74) 4.55 (1.08) 2.41 0.018 * 0.26
Cocaine 3.56 (1.42) 2.24 (1.51) 5.53 <0.001 ** 0.86
Motives for cannabis use
Enhancement 16.35 (3.94) 15.44 (5.30) 2.24 0.028 * 0.26
Conformity 7.25 (1.12) 5.40 (1.87) 14.60 <0.001 * 1.68
Expansion 11.89 (5.42) 11.45 (6.05) 1.17 0.244 -
Coping 9.23 (3.74) 8.59 (4.27) 1.69 0.096 -
Social 10.32 (3.64) 9.07 (3.49) 3.98 <0.001 ** 0.45
* p < 0.05; ** p < 0.001.
Table 3. Correlations between cannabis withdrawal symptoms (CWS) and cannabis use motives.
Time 1 Time 2
Enhancement Conformity Expansion Coping Social Enhancement Conformity Expansion Coping Social
CWS 0.161 0.186 0.168 0.338 * 0.166 0.037 0.135 0.056 0.327 * 0.007
* p < 0.05.
4. Discussion
The main goal of this retrospective study was to analyze changes in the pattern of
cannabis use in the Spanish population, focusing mainly on the motivations for using
cannabis and withdrawal symptoms during the confinement associated with the state of
alarm in Spain. To our knowledge, no previous research has analyzed this phenomenon
in Spain. Contrary to previous studies [3,9–12], and on average, no significant changes in
the frequency of cannabis or tobacco use were observed among Spanish users during the
lockdown, despite a slight overall decrease in the frequency. However, significantly more
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participants abstained from tobacco use, and 8% began to abstain from cannabis use. In
addition, significant decreases were detected in the use of all forms of cannabis, except in
the use of CBD products, which remained stable. These results are not surprising given the
significant decreases in the perceived availability of all drugs and the significant increases
in the cannabis price reported by participants, in line with the difficulties in accessing
cannabis previously reported [19].
Accordingly, cannabis users also reported significant changes in the sources used to
obtain cannabis, with significant decreases in the use of traditional sources (friends, families,
dealers and cannabis clubs). However, significantly more cannabis consumers used the
Internet as a source of cannabis or cannabis products, although this figure still represented
only 6.7% of participants. This result is consistent with recent studies that highlight the
fact that, in the first months of 2020, online cannabis sales increased by 27%, anticipating
the negative consequences of the COVID-19 pandemic on social interaction [20,25]. This
information represents a relevant issue, considering the fact that, as a consequence of the
social isolation due to the pandemic, more cannabis users are becoming familiar with new
sources of cannabis supplies [20].
In addition, these difficulties in obtaining cannabis seem to have had an impact
also on the motives for cannabis use. Surprisingly, cannabis use for the purposes of
enhancement, conformity or social reasons decreased significantly during confinement,
while cannabis use for expansion or coping remained stable. Our results also indicate
that, both before and during the state of alarm and national confinement, those reporting
cannabis use with coping motives experienced significantly more cannabis withdrawal
symptoms. This result is important, considering that, traditionally, motivations for cannabis
use are a determinant for understanding cannabis use problems and disorders [14–16] and,
in particular, coping as a motivation for cannabis use represents a marker for increased
cannabis use as well as higher risk of problematic use [14,26]. This is in line with other
studies highlighting that those individuals relying on cannabis consumption to manage
their negative emotions usually show greater cannabis withdrawal symptom severity and
less self-efficacy in refraining from using cannabis in emotionally distressing situations,
such as the COVID-19 pandemic, where anxiety, depression and stress levels have risen
due to national lockdowns [27,28].
Our study has some limitations which mean that the results need to be interpreted
with caution. Firstly, our research enrolled more men than women, which could limit the
representativeness of the cannabis-using population; nonetheless, reports in Spain have
found that males are more likely than females to use cannabis [29]. Secondly, the sample
was of moderate size (N = 89). The use of a larger sample could have allowed for the
detection of further changes in cannabis use. Finally, in order to analyze the participants’
reasons for consuming cannabis, we used a well-known standardized tool (the Spanish
version of the MMM) that evaluates the main motivations for cannabis consumption (i.e.,
social, enhancement, coping, expansion and conformity reasons). Nonetheless, such a tool
does not provide for an exploration of other motivations for cannabis use such as medical
concerns, and such information was not collected.
5. Conclusions
In conclusion, results from the present study enhance the necessity of investing in
resources that support harm reduction strategies and cannabis cessation programs [18], es-
pecially in problematic social situations (such as the COVID-19 pandemic) where additional
health problems could inadvertently arise, such as increased substance use [3,18]. This
information could provide us with useful clinical information on the behavior of cannabis
users, not only in possible further COVID outbreaks, but also in common clinical practice.
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